According to TipRanks, Roy is a 4-star analyst with an average return of 5.2% and a 32.82% success rate. Roy covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Aileron Therapeutics, and Adicet Bio.
Chimerix has an analyst consensus of Strong Buy, with a price target consensus of $8.00, representing a 238.98% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.
Based on Chimerix’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $15 thousand and a GAAP net loss of $24.77 million. In comparison, last year the company earned revenue of $1.44 million and had a GAAP net loss of $97.42 million
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Read More on CMRX:
- INTERNATIONAL LAND ALLIANCE, INC. ANNOUNCES LISTING OF EMERALD GROVE FOR $2.8M
- Susquehanna Remains a Buy on Micron (MU)
- SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15
- REMINDER/Stella-Jones Will Hold a Conference Call to Discuss Its Second Quarter 2022 Financial Results
- NaturalShrimp Issues Technology Update